Targeted Screening for Taenia Solium Tapeworms

Taenia Solium Taeniasis Clinical Trial

Official title:

Targeted Screening for Taenia Solium Tapeworms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01296958
• Other study ID #: 1R21NS069275-01
• Secondary ID: 1R21NS069275-01
• Status: Completed
• Phase: N/A
• First received: February 15, 2011
• Last updated: October 22, 2014
• Start date: May 2011
• Est. completion date: January 2013

Study information

• Verified date: October 2014
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1811
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All community members are eligible

Exclusion Criteria:

• Inability to provide informed consent

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

• Taenia Solium Taeniasis

Intervention

Drug:
• Niclosamide
Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)

Behavioral:
• Community education campaign
Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.

Locations

Country	Name	City	State
Peru	San Marcos University	Lima

Sponsors (3)

Lead Sponsor	Collaborator
Oregon Health and Science University	National Institute of Neurological Disorders and Stroke (NINDS), Universidad Nacional Mayor de San Marcos

Country where clinical trial is conducted

Peru, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Porcine seroprevalence		Every 4 months	No
Secondary	Intestinal tapeworm prevalence		16 months	No